Updated Approaches against SARS-CoV-2

• Published in: Antimicrobial agents and chemotherapy Vol. 64; no. 6
• Main Authors: Li, Haiou, Zhou, Yunjiao, Zhang, Meng, Wang, Haizhou, Zhao, Qiu, Liu, Jing
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 21.05.2020
• Subjects: Betacoronavirus; Coronavirus Infections; Coronavirus Infections - immunology; Coronavirus Infections - prevention & control; Coronavirus Infections - therapy; COVID-19; Humans; Inflammation - prevention & control; Medicine, Chinese Traditional; Minireview; Pandemics - prevention & control; Pneumonia, Viral; Pneumonia, Viral - immunology; Pneumonia, Viral - prevention & control; Pneumonia, Viral - therapy; SARS-CoV-2; Virus Internalization; Virus Replication; COVID-19; antiviral drugs; treatment; SARS-CoV-2; vaccines
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/AAC.00483-20

Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in virology, epidemiology, and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing to develop a treatment for COVID-19. Recent studies have revealed many attractive therapeutic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in virology, epidemiology, and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing to develop a treatment for COVID-19. Recent studies have revealed many attractive therapeutic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. In this minireview, we aim to summarize the updated potential approaches against SARS-CoV-2. We emphasize that further efforts are warranted to develop the safest and most effective approach.